JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Recombinant Human anti-SARS-CoV-2 Spike-RBD (002-S21F2) is expressed in XtenCHO. This receptor-binding domain (RBD) targeting human antibody (002-S21F2) effectively neutralizes live viral isolates of SARS-CoV-2 variants of concern (VOCs) including Alpha, Beta, Gamma, Delta, and Omicron (BA.1 and BA.2) with IC50 ranging from 0.02 – 0.05 μg/ml. This antibody was isolated by screening COVID-19-recovered individuals who had experienced mild symptoms after the ancestral Wuhan strain (WA.1) transmission in the year 2020. Antibody 002-S21F2 was the most potent mAb that neutralized live SARS-CoV-2 WA.1 . Antibody 002-S21F2 has unique genetic features distinct from any reported SARS-CoV-2 mAbs. Structural studies of the full-length IgG in complex with spike trimers (Omicron and WA.1) reveal that 002-S21F2 recognizes an epitope on the outer face of RBD (class-3 surface), outside the ACE2 binding motif which enable it to overcome mutations found in the Omicron variants.
BA.2 RBD: 19.21 ng/mlOmicron RBD: 26.48 ng/mlXBB RBD: 6.862 mg/ml